Abstract
BACKGROUND AND PURPOSE: Treatment of ruptured blister-like aneurysms is technically challenging. This study aimed at analyzing the safety and efficacy of the Flow-Redirection Endoluminal Device (FRED) in the treatment of ruptured blister-like aneurysms.
MATERIALS AND METHODS: In a retrospective multicenter study, all patients treated with the FRED due to a ruptured intracranial blister-like aneurysm between January 2013 and May 2019 were analyzed. The primary end points for clinical safety were mRS 0–2 at 6 months after treatment and the absence of major ipsilateral stroke or death. The primary end points for efficacy were the absence of rebleeding after treatment and complete angiographic occlusion according to the O’Kelly-Marotta classification at 6 months after treatment.
RESULTS: In total, 30 patients with 30 ruptured blister-like aneurysms were treated. Immediate complete aneurysm obliteration (O’Kelly-Marotta classification D) with the FRED was achieved in 10 patients (33%). Of the 26 patients with follow-up, complete obliteration was achieved in 21 patients (80%) after 6 months and in 24 patients (92%) in the final follow-up (median, 22 months). Twenty-three patients (77%) achieved mRS 0–2 at 6 months. Major stroke or death occurred in 17%. Two patients died due to pneumonia, and 2 patients died due to infarction following cerebral vasospasm. There was no case of rebleeding after FRED implantation. There was 1 case of delayed asymptomatic stent occlusion.
CONCLUSIONS: Treatment of ruptured blister-like aneurysms with the FRED is safe and effective.
ABBREVIATIONS:
- OKM
- O’Kelly-Marotta
- FRED
- Flow-Redirection Endoluminal Device
- PED
- Pipeline Embolization Device
Footnotes
M.A. Möhlenbruch and F. Seker contributed equally to this work.
Paper previously presented at: World Federation of Interventional and Therapeutic Neuroradiology Congress, October 21–24, 2019; Naples, Italy.
Disclosures: Markus A. Möhlenbruch—UNRELATED: Consultancy: Medtronic, MicroVention, Stryker*; Grants/Grants Pending: Balt, Medtronic, MicroVention, Stryker*; Payment for Lectures Including Service on Speakers Bureaus: Medtronic, MicroVention, Stryker.* Christoph J. Griessenauer—UNRELATED: Consultancy: Stryker; Employment: Geisinger. Martin Bendszus—UNRELATED: Board Membership: Data and Safety Monitoring Board for Vascular Dynamics, Boehringer; Consultancy: Codman, Braun; Grants/Grants Pending: DFG, EU, Hopp Foundation, Novartis, Siemens, Stryker, Guerbet*; Payment for Lectures Including Service on Speakers Bureaus: Novartis, Teva Pharmaceutical Industries, Codman, Guerbet, Merck, Grifols, Bayer. Naci Kocer—UNRELATED: Other: proctoring and consultant agreement with MicroVention. Monika Killer-Oberpfalzer—RELATED: Grant: research grant from MicroVention/Terumo*; *Money paid to the institution.
- © 2020 by American Journal of Neuroradiology